The University of Texas Health Science Center at San Antonio
Casey Straud
The primary goal of this pilot project is to demonstrate the safety and feasibility of using Cannabidiol (CBD) in combination with standard of care prolonged exposure (PE) psychotherapy to reduce PTSD symptoms.
Posttraumatic Stress Disorder
Stress Disorders, Post-Traumatic
Cannabidiol (CBD) oral solution
Placebo
Massed Prolonged Exposure (mPE)
Phase 1
Phase 2
This study is an early Phase II double-blind, pilot randomized controlled clinical trial. The study team will use a permuted block randomization design stratified by a Posttraumatic Stress Disorder (PTSD) severity median score on the PTSD Checklist (PCL-5) derived from a recently completed STRONG STAR repository. Participants will be 24 individuals with PTSD to investigate the safety, feasibility, and PTSD symptom change associated with CBD 250mg taken twice a day for 18 days (n=12) vs. placebo (n=12) in combination with a standard of care, 10-sessions massed PE psychotherapy administered over 2 weeks. Aims 2 and 3 will evaluate biochemical and physiological outcomes associated with the brain endocannabinoid (eCB) and PTSD that may be affected by CBD. Permuted block randomization is advantageous in small clinical trials to ensure equal allocation of participants in each condition. Participant randomization will be subdivided into randomized blocks of four, two patients in each block will be assigned to CBD and two will be assigned to placebo.}}
Study Type : | Interventional |
Estimated Enrollment : | 22 participants |
Masking : | Double |
Masking Description : | A compounding pharmacy will supply both the study drug and a matching strawberry flavored liquid. |
Primary Purpose : | Treatment |
Official Title : | Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder: A Pilot Study |
Actual Study Start Date : | April 4, 2022 |
Estimated Primary Completion Date : | June 30, 2023 |
Estimated Study Completion Date : | June 30, 2023 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Cannabidiol (CBD) Epidiolex oral solution 500mg (5ml) per day |
Drug: Cannabidiol (CBD) oral solution Behavioral: Massed Prolonged Exposure (mPE) |
Placebo Comparator: Placebo Placebo oral solution 5ml per day |
Drug: Placebo Behavioral: Massed Prolonged Exposure (mPE) |
Ages Eligible for Study: | 18 Years to 65 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
University of Texas Health Science Center at San Antonio - STRONG STAR Northwest Center
Saint Anthony, Texas, United States, 78229